(PRWEB) June 25, 2012
The US Drug Watchdog says, "The osteoporosis drug called Fosamax, and out of the blue femur breaks is one of the most complicated issues we have ever encountered. For one, we are hearing from women, who were using Fosamax for five years or more, their femur broke, and typically they had to have at least one surgery to repair the femur. Often, if not in most cases these surgeries involve using a metal rod to reinforce the femur. Our greatest fear is most women, who have had this happen will never hear about the possible correlation between the osteoporosis drug called Fosamax, and their broken femur. We are urging family members of women, who have suffered a broken femur, to ask if they were also using Fosamax." On February 3rd 2011, The Journal of the American Medical Association (JAMA) came out with a Canadian medical study that points to a higher risk of a certain type of thighbone fracture in women who take bisphosphonates such as Fosamax for long periods. The US Drug Watchdog wants to hear from any woman, who was using the osteoporosis drug called Fosamax for five years, or more, and then suffered an unexplained femur break, also known as a thighbone break-with the hope they get all victims to the best possible attorneys. For more information please contact the US Drug Watchdog at 866-714-6466, or contact the group via their web site at http://USDrugWatchdog.Com
The US Drug Watchdog says, "We want to make certain all Fosamax users, or other osteoporosis type drug users, who suffered an unexplained broken femur, or thigh bone get to the best actual trial law firms or attorneys, that have a superior record in achieving significant results for their clients--period." For more information please contact the US Drug Watchdog anytime at 866-714-6466, or contact the group via its web site at http://USDrugWatchdog.Com
MDL No. 2243-In re: Fosamax (Alendronate Sodium) Products Liability Litigation (No. II)
Read the full story at http://www.prweb.com/releases/2012/6/prweb9630710.htm.
Copyright©2012 Vocus, Inc.
All rights reserved